Michael Krimm

421 total citations
9 papers, 88 citations indexed

About

Michael Krimm is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Michael Krimm has authored 9 papers receiving a total of 88 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Radiology, Nuclear Medicine and Imaging, 6 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Michael Krimm's work include Monoclonal and Polyclonal Antibodies Research (8 papers), HER2/EGFR in Cancer Research (3 papers) and Glycosylation and Glycoproteins Research (2 papers). Michael Krimm is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), HER2/EGFR in Cancer Research (3 papers) and Glycosylation and Glycoproteins Research (2 papers). Michael Krimm collaborates with scholars based in Netherlands and United States. Michael Krimm's co-authors include Olga Vasiljeva, Margaret Nguyen, Guus A.M.S. van Dongen, Daniëlle J. Vugts, Julja Burchard, Jerome Hochman, Alan B. Sachs, Jie Wei, Nelly A. Kuklin and Jeffrey J. Jones and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Molecular Pharmacology.

In The Last Decade

Michael Krimm

9 papers receiving 81 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Krimm Netherlands	5	51	39	29	15	13	9	88
Pei Rong Evelyn Lee United States	3	39 0.8×	42 1.1×	26 0.9×	10 0.7×	9 0.7×	3	91
Scialini Colombi Italy	4	48 0.9×	50 1.3×	8 0.3×	13 0.9×	5 0.4×	8	86
Elana Ernstoff United States	2	70 1.4×	61 1.6×	31 1.1×	8 0.5×	15 1.2×	2	122
Huai-Chin Chiang United States	7	66 1.3×	43 1.1×	13 0.4×	39 2.6×	22 1.7×	14	128
Julia Paton‐Hough United Kingdom	5	29 0.6×	73 1.9×	15 0.5×	15 1.0×	8 0.6×	5	112
Aarti Kolluri United States	3	53 1.0×	28 0.7×	10 0.3×	21 1.4×	15 1.2×	5	97
Hannah Riva United States	2	36 0.7×	26 0.7×	14 0.5×	8 0.5×	2 0.2×	10	61
Mackenzie Fuller United States	3	36 0.7×	17 0.4×	9 0.3×	10 0.7×	5 0.4×	4	66
Christina Heichler Germany	4	29 0.6×	25 0.6×	7 0.2×	13 0.9×	6 0.5×	5	94
Maihi Fujita United States	2	24 0.5×	28 0.7×	7 0.2×	8 0.5×	22 1.7×	6	55

Countries citing papers authored by Michael Krimm

Since Specialization

Citations

This map shows the geographic impact of Michael Krimm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Krimm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Krimm more than expected).

Fields of papers citing papers by Michael Krimm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Krimm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Krimm. The network helps show where Michael Krimm may publish in the future.

Co-authorship network of co-authors of Michael Krimm

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Krimm. A scholar is included among the top collaborators of Michael Krimm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Krimm. Michael Krimm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Berezhnoy, Alexey, Hsin Wang, Na Cai, et al.. (2022). 1078 Conditionally activatable interferon-alpha 2b improves tolerability and exhibits preferential activity in tumors. Regular and Young Investigator Award Abstracts. A1120–A1120. 1 indexed citations

Berezhnoy, Alexey, Hsin Wang, Michael B. Winter, et al.. (2022). Abstract 2071: Probody-interferon-alpha 2b combines antitumor activity with improved tolerability. Cancer Research. 82(12_Supplement). 2071–2071. 1 indexed citations

Berezhnoy, Alexey, Hsin Wang, Hikmat Assi, et al.. (2021). 706 Conditional cytokine therapeutics for tumor-selective biological activity: preclinical characterization of a dual-masked IFN-a2b. SHILAP Revista de lepidopterología. A735–A735. 6 indexed citations

Winter, Michael B., et al.. (2021). Novel Ex Vivo Zymography Approach for Assessment of Protease Activity in Tissues with Activatable Antibodies. Pharmaceutics. 13(9). 1390–1390. 5 indexed citations

Nguyen, Margaret, et al.. (2020). The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by ⁸⁹Zr-immuno-PET in xenograft bearing mice. Theranostics. 10(13). 5815–5828. 27 indexed citations

Scolan, Erwan Le, Tiffany Tse, Michael Krimm, et al.. (2019). Abstract 3202: A probody drug conjugate targeting CD166 (ALCAM) enhances preclinical antitumor activity of a probody therapeutic targeting PD-1. Cancer Research. 79(13_Supplement). 3202–3202. 2 indexed citations

Singh, Shweta, Jason Sagert, Michael Krimm, et al.. (2016). Abstract 2975: Development of a probody drug conjugate (PDC) targeting CD71 for the treatment of solid tumors and lymphomas. Cancer Research. 76(14_Supplement). 2975–2975. 5 indexed citations

Desnoyers, Luc, Annie Yang, Tony W. Liang, et al.. (2013). Abstract 4570: Development of a proteolytically activatable EGFR Probody for cancer therapy.. Cancer Research. 73(8_Supplement). 4570–4570. 1 indexed citations

Wei, Jie, Jeffrey J. Jones, Jing Kang, et al.. (2011). RNA-Induced Silencing Complex-Bound Small Interfering RNA Is a Determinant of RNA Interference-Mediated Gene Silencing in Mice. Molecular Pharmacology. 79(6). 953–963. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact